Vascular-access complication
Sixteen trials of 5 agents of HIF-PHIs reported vascular-access complications of HIF-PHIs for DD CKD anemia, containing 13,915 participants[2, 12, 16, 26, 27, 29-32, 35, 36, 38-40]. Compared with ESAs, Daprodustat performed much better in the risk of vascular-access complication (RR: 0.78, 95% CI: 0.66-0.92, p<0.01, I2=0.3%), while Roxadustat performed a little worse (RR: 1.15, 95% CI: 1.04-1.27, p<0.01, I2=0.3%). The pooled results showed no significant difference in Enarodustat, Vadadustat, and Molidustat (Figure 4).